Distinguished in Pancreatic Islet Cell Tumor

Patricia Niccoli

Marseille, FR 
Distinguished in Pancreatic Islet Cell Tumor
Marseille, FR 
OverviewLocationsClinical Research

Overview

Patricia Niccoli practices in Marseille, France. Ms. Niccoli is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Metastatic Insulinoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Her clinical research consists of co-authoring 50 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 12 articles in the study of Pancreatic Islet Cell Tumor.

Gender
Female

Locations

Marseille, France
Other Locations
Saint-etienne, 13273, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Folfiri+Bevacizumab, Folfiri
Study Phase: Phase 2
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
Enrollment Status: Completed
Publish Date: November 04, 2022
Intervention Type: Drug
Study Phase: Not Applicable
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Enrollment Status: Completed
Publish Date: August 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

50 Total Publications

Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors.
Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors.
Journal: Frontiers in endocrinology
Published: January 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Niccoli's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile